KCNQ2 Developmental and Epileptic Encephalopathy

Mendelian MONDO:0013387 Pathograph 7 Show in embeddings browser Epilepsy Neurodevelopmental Disorder Neurological Disease

KCNQ2 developmental and epileptic encephalopathy (KCNQ2-NEO-DEE, DEE7) is the severe end of the KCNQ2-related disorder continuum, whose mild end is self-limited (benign) familial neonatal epilepsy. It presents with multiple daily, mostly tonic seizures beginning in the first week of life, a burst-suppression or multifocal epileptiform EEG, and moderate-to-profound developmental impairment. KCNQ2 encodes the Kv7.2 subunit of the neuronal M channel, which carries the slow, non-inactivating M-current that stabilizes the resting membrane potential and restrains repetitive firing. NEO-DEE is caused by heterozygous (usually de novo) pathogenic variants that impair M channel function, most often by a dominant-negative mechanism (some variants are instead gain-of-function), whereas the benign end results from milder loss-of-function/haploinsufficiency. Seizures typically remit between about nine months and four years of age, but the developmental encephalopathy persists.

Ask OpenScientist

Ask a research question about KCNQ2 Developmental and Epileptic Encephalopathy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
6
Pathophys.
6
Phenotypes
3
Gaps
7
Pathograph
1
Genes
3
Medical Actions
1
References
1
Deep Research
🔗

Mappings

MONDO
MONDO:0013387 developmental and epileptic encephalopathy, 7
skos:exactMatch MONDO
MONDO:0013387 is the KCNQ2 (DEE7) developmental and epileptic encephalopathy concept.
👪

Inheritance

1
Autosomal dominant inheritance HP:0000006
KCNQ2-related disorders are inherited in an autosomal dominant manner. Most individuals with KCNQ2-NEO-DEE have a de novo pathogenic variant.
Autosomal dominant inheritance
Show evidence (2 references)
PMID:20437616 SUPPORT Human Clinical
"KCNQ2-related disorders are inherited in an autosomal dominant manner."
GeneReviews establishes autosomal dominant inheritance of KCNQ2 disorders.
PMID:20437616 SUPPORT Human Clinical
"Most individuals diagnosed with KCNQ2-NEO-DEE have a de novo pathogenic variant."
GeneReviews documents that KCNQ2-NEO-DEE is usually de novo.
?

Discussions and Knowledge Gaps

3
KCNQ2-NEO-DEE is caused by both dominant-negative loss-of-function and gain-of-function variants, which have opposite biophysical effects on the M channel yet converge on a severe encephalopathy - how does gain-of-function cause disease, and can functional variant classification reliably direct the opposite therapies (M channel opener for loss-of-function, avoidance or negative modulation for gain-of-function) each requires?
KNOWLEDGE GAP OPEN gap_kcnq2_gof_vs_lof_opposite_drugs
Attached to
pathophysiology#KCNQ2 Pathogenic Variant pathophysiology#Neuronal M Channel Dysfunction
Most NEO-DEE variants are dominant-negative and reduce M-current, so a Kv7 opener is the mechanistically correct drug. But a minority are gain-of-function, which increase potassium current and would be worsened by an opener, plausibly requiring the opposite pharmacology. Because the drug that helps one class can harm the other, reliable functional classification of each variant is clinically decisive, not merely academic, yet a validated rapid variant-to-drug assignment pathway does not exist. Resolving how gain-of-function produces encephalopathy and how to triage variants to opener versus non-opener strategies is the central precision-therapy gap.
Proposed experiments
Functional-class-guided drug response in KCNQ2-DEE models
variant functional classification and drug-response experiment
exp_kcnq2_variant_functional_triage
Classify a panel of NEO-DEE variants as loss-of-function, dominant-negative, or gain-of-function by electrophysiology in heterologous cells and patient iPSC-derived neurons, then test Kv7-opener versus Kv7-blocker responses to determine whether functional class predicts the correct pharmacology.
Readouts
Drug response by functional class
pathophysiology#Neuronal M Channel Dysfunction
Regulation of membrane potential GO:0042391 ↕ DYSREGULATED
patch clamp recording multielectrode array recording
Direction: POSITIVE
Controls
Wild-type KCNQ2 channels
Wild-type Kv7.2/7.3 channels as the normalization reference.
Decision criterion
Functional triage is supported if Kv7 openers normalize excitability for loss-of-function and dominant-negative variants but worsen it for gain-of-function variants, establishing variant class as a treatment selector.
Would support
pathophysiology#Neuronal M Channel Dysfunction
Show evidence (1 reference)
DOI:10.1111/epi.17627 SUPPORT Human Clinical
"Five individuals had daily seizures at baseline and experienced at least 50% seizure reduction with treatment, sustained in four."
Shows the M channel opener helps loss-of-function-driven seizures; the open question is whether the same drug is contraindicated in gain-of-function variants, requiring functional triage.
What distinguishes the benign self-limited end of the KCNQ2 spectrum (self-limited familial neonatal epilepsy, modeled in the Benign Neonatal Seizures entry) from the severe NEO-DEE end, given that both arise from variants in the same gene?
KNOWLEDGE GAP OPEN gap_kcnq2_same_gene_opposite_severity
Attached to
pathophysiology#KCNQ2 Pathogenic Variant pathophysiology#Neuronal M Channel Dysfunction
KCNQ2 produces a phenotypic continuum from a benign, self-limited neonatal epilepsy with normal development to a severe developmental and epileptic encephalopathy. The prevailing explanation is that the benign end reflects simple haploinsufficiency or mild loss-of-function while the severe end reflects dominant-negative suppression (or gain-of-function), producing a larger M-current deficit. But this genotype-to-severity map is incomplete, and it is the same open question posed from the mild side in the Benign Neonatal Seizures entry. A quantitative rule linking residual M-current to outcome would let the neonatal genetic diagnosis predict prognosis.
Proposed experiments
Residual M-current versus clinical severity mapping
genotype-to-severity correlation experiment
exp_kcnq2_residual_current_severity_map
Across a large set of benign-end and NEO-DEE variants, quantify residual M-current (accounting for dominant-negative co-assembly) and correlate it with clinical severity and developmental outcome to test whether a current-deficit threshold separates the benign from the severe phenotype.
Readouts
Residual current versus outcome
pathophysiology#Neuronal M Channel Dysfunction
patch clamp recording
Direction: POSITIVE
Controls
Benign-end variants
Self-limited-epilepsy variants as the mild-end comparator.
Decision criterion
A severity determinant is supported if residual M-current (or the degree of dominant-negative suppression) separates benign-end from NEO-DEE variants and tracks developmental outcome.
Would support
pathophysiology#KCNQ2 Pathogenic Variant
Show evidence (1 reference)
PMID:22275249 SUPPORT Human Clinical
"KCNQ2 and KCNQ3 mutations are known to be responsible for benign familial neonatal seizures (BFNS)."
Anchors the shared-gene continuum: the same gene underlies the benign end, and the severe NEO-DEE end emerged as a distinct phenotype of the same gene, framing the severity-determinant gap.
Why do KCNQ2-NEO-DEE seizures typically remit between about nine months and four years of age while the developmental encephalopathy persists, and is the developmental impairment driven by the neonatal seizures and M-current loss during a critical window (and therefore reducible by early variant-appropriate treatment) or by a seizure-independent developmental role of the M channel?
KNOWLEDGE GAP OPEN gap_kcnq2_seizure_remission_vs_persistent_encephalopathy
Attached to
pathophysiology#Neonatal-Onset Developmental Encephalopathy pathophysiology#Neonatal-Onset Seizures with Burst-Suppression EEG
The dissociation between remitting seizures and a persistent encephalopathy is a defining and puzzling feature of NEO-DEE. If the developmental impairment is largely caused by the neonatal seizures and the M-current deficit acting during an early critical window, then rapid neonatal genetic diagnosis and early variant-appropriate therapy could improve developmental outcome. If instead the M channel has a seizure-independent developmental role, cognitive prognosis would be more fixed. This determines how much developmental benefit to expect from the treat-early-and-right strategy.
Proposed experiments
Early variant-appropriate treatment and developmental outcome
early-treatment developmental-outcome experiment
exp_kcnq2_early_treatment_developmental_outcome
In a KCNQ2-NEO-DEE knock-in model, apply variant-appropriate therapy (M channel opener for loss-of-function, or seizure suppression) at graded ages spanning the neonatal window and measure whether earlier seizure control improves cognitive and behavioral outcome independently of later seizure remission.
Readouts
Cognitive outcome by treatment timing
pathophysiology#Neonatal-Onset Developmental Encephalopathy
behavioral assay electroencephalography
Direction: POSITIVE
Controls
Untreated and wild-type
Matched untreated mutants and wild-type controls.
Decision criterion
A seizure/window-driven contribution is supported if earlier treatment improves developmental outcome beyond its effect on later seizure remission; a seizure-independent developmental role is supported if outcome is unchanged by treatment timing.
Would support
pathophysiology#Neonatal-Onset Developmental Encephalopathy
Show evidence (1 reference)
PMID:32239694 SUPPORT Model Organism
"displays spontaneous generalized seizures and cognitive impairment"
Provides a model in which seizures and cognitive impairment co-occur, a system in which the causal contribution of seizures versus intrinsic channel dysfunction to the developmental deficit could be dissected.
⚙

Pathophysiology

6
KCNQ2 Pathogenic Variant
A heterozygous, usually de novo pathogenic variant in KCNQ2 (most often a missense variant in the voltage sensor or pore of the Kv7.2 subunit) alters the neuronal M channel. In NEO-DEE these variants typically act by a dominant-negative mechanism, and a minority are gain-of-function; the milder benign end of the spectrum results from simple loss-of-function or haploinsufficiency. This node captures the single concept of the initiating genetic lesion.
KCNQ2 hgnc:6296
Downstream
Neuronal M Channel Dysfunction The variant alters the Kv7.2-containing neuronal M channel.
Show evidence (1 reference)
PMID:22275249 SUPPORT Human Clinical
"We found 7 different heterozygous KCNQ2 mutations in 8 patients (8/80; 10%); 6 mutations arose de novo."
The Weckhuysen series established de novo heterozygous KCNQ2 missense variants as the cause of the neonatal epileptic encephalopathy phenotype.
Neuronal M Channel Dysfunction
KCNQ2 (Kv7.2) co-assembles with KCNQ3 (Kv7.3) to form the neuronal M channel. Pathogenic variants reduce or alter M channel function; a dominant-negative subunit can suppress channels beyond simple haploinsufficiency. This node captures the single concept of the channel defect and conforms to the shared epilepsy ion-channel node.
Neuron CL:0000540
Potassium channel activity GO:0005267 ↓ DECREASED
Downstream
Loss of M-Current Control of Neuronal Excitability Reduced M channel function lowers the slow M-current that regulates excitability.
Loss of M-Current Control of Neuronal Excitability
The M-current is a slow, non-inactivating potassium current that stabilizes the resting membrane potential and provides a brake on repetitive action-potential firing. Its reduction removes this brake, depolarizing neurons and permitting sustained firing. This node captures the single concept of the excitability-control failure.
Neuron CL:0000540
Regulation of membrane potential GO:0042391 ↕ DYSREGULATED
Downstream
Neuronal Hyperexcitability Loss of the M-current brake renders neurons hyperexcitable.
Neuronal Hyperexcitability
Neurons deprived of adequate M-current become hyperexcitable and prone to hypersynchronous discharges. This node captures the single concept of network hyperexcitability and conforms to the shared epilepsy final common pathway.
Neuron CL:0000540
Downstream
Neonatal-Onset Seizures with Burst-Suppression EEG Hyperexcitable neonatal networks produce the seizures and burst-suppression EEG of NEO-DEE.
Neonatal-Onset Developmental Encephalopathy Early network dysfunction during a critical developmental window contributes to the developmental encephalopathy.
Neonatal-Onset Seizures with Burst-Suppression EEG
The clinical endpoint is multiple daily, mostly tonic seizures beginning in the first week of life, accompanied by a burst-suppression or multifocal epileptiform EEG. This node captures the single concept of the seizure endpoint and conforms to the shared epilepsy final common pathway.
Neuron CL:0000540
Show evidence (2 references)
PMID:20437616 SUPPORT Human Clinical
"KCNQ2-NEO-DEE is characterized by multiple daily seizures beginning in the first week of life that are mostly tonic, with associated focal motor and autonomic features."
GeneReviews documents the neonatal-onset multiple daily tonic seizures of NEO-DEE.
PMID:20437616 SUPPORT Human Clinical
"At onset, EEG shows a burst-suppression pattern or multifocal epileptiform activity; early brain MRI can show basal ganglia hyperdensities and later MRIs may show white matter or general volume loss."
GeneReviews documents the burst-suppression / multifocal EEG at onset.
Neonatal-Onset Developmental Encephalopathy
Moderate-to-profound developmental impairment is present and persists even after seizures remit (typically between about nine months and four years of age), reflecting an encephalopathy that outlasts the active epilepsy. This node captures the single concept of the developmental outcome.
Neuron CL:0000540
Show evidence (1 reference)
PMID:32239694 SUPPORT Model Organism
"displays spontaneous generalized seizures and cognitive impairment"
A recurrent-variant knock-in mouse reproduces both the seizures and the cognitive impairment, supporting a causal link from M channel dysfunction to the developmental encephalopathy.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for KCNQ2 Developmental and Epileptic Encephalopathy Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

6
Nervous System 5
Neonatal-Onset Seizures Seizure HP:0001250
Show evidence (1 reference)
PMID:20437616 SUPPORT Human Clinical
"KCNQ2-NEO-DEE is characterized by multiple daily seizures beginning in the first week of life that are mostly tonic, with associated focal motor and autonomic features."
GeneReviews documents neonatal-onset multiple daily seizures.
Tonic Seizures Tonic seizure HP:0032792
EEG with Burst Suppression EEG with burst suppression HP:0010851
Show evidence (1 reference)
PMID:20437616 SUPPORT Human Clinical
"At onset, EEG shows a burst-suppression pattern or multifocal epileptiform activity; early brain MRI can show basal ganglia hyperdensities and later MRIs may show white matter or general volume loss."
GeneReviews documents the burst-suppression EEG at onset.
Global Developmental Delay Global developmental delay HP:0001263
Intellectual Disability Intellectual disability HP:0001249
Respiratory 1
Apnea Apnea HP:0002104
🧬

Genetic Associations

1
KCNQ2
Gene: KCNQ2 hgnc:6296 relationship_type: CAUSATIVE
Show evidence (1 reference)
PMID:20437616 SUPPORT Human Clinical
"Most individuals diagnosed with KCNQ2-NEO-DEE have a de novo pathogenic variant."
GeneReviews documents the de novo origin of most KCNQ2-NEO-DEE.
💊

Medical Actions

3
Sodium Channel Blocker Therapy
Action: Pharmacotherapy NCIT:C15986
Agent: carbamazepine CHEBI:3387 phenytoin CHEBI:8107
Sodium channel blockers (e.g., carbamazepine, phenytoin) are preferentially effective in KCNQ2-NEO-DEE; seizure freedom is more likely with these agents than with other antiseizure medications - a precision-therapy contrast with Dravet syndrome, where sodium channel blockers are avoided.
Show evidence (1 reference)
PMID:20437616 SUPPORT Human Clinical
"Seizure freedom is more likely achieved when receiving sodium channel blockers."
GeneReviews documents the preferential efficacy of sodium channel blockers in KCNQ2-NEO-DEE.
M-Channel Opener Therapy
Action: Pharmacotherapy NCIT:C15986
Agent: ezogabine CHEBI:68584
Kv7/M-channel openers (the prototype ezogabine/retigabine) are the mechanistically targeted approach, directly augmenting the deficient M-current; ezogabine was withdrawn from market, and next-generation Kv7 activators are in development.
Show evidence (1 reference)
DOI:10.1111/epi.17627 SUPPORT Human Clinical
"Five individuals had daily seizures at baseline and experienced at least 50% seizure reduction with treatment, sustained in four."
A retrospective series found that the M channel opener ezogabine reduced seizures in KCNQ2-DEE, the mechanistically targeted therapy for loss-of-function variants.
Antiseizure Medication
Action: Pharmacotherapy NCIT:C15986
Multiple antiseizure medications are used; NEO-DEE seizures may be resistant to combinations.
{ }

Source YAML

click to show 
name: KCNQ2 Developmental and Epileptic Encephalopathy
creation_date: "2026-07-17T00:00:00Z"
category: Mendelian
description: >-
  KCNQ2 developmental and epileptic encephalopathy (KCNQ2-NEO-DEE, DEE7) is the
  severe end of the KCNQ2-related disorder continuum, whose mild end is
  self-limited (benign) familial neonatal epilepsy. It presents with multiple
  daily, mostly tonic seizures beginning in the first week of life, a
  burst-suppression or multifocal epileptiform EEG, and moderate-to-profound
  developmental impairment. KCNQ2 encodes the Kv7.2 subunit of the neuronal M
  channel, which carries the slow, non-inactivating M-current that stabilizes
  the resting membrane potential and restrains repetitive firing. NEO-DEE is
  caused by heterozygous (usually de novo) pathogenic variants that impair M
  channel function, most often by a dominant-negative mechanism (some variants
  are instead gain-of-function), whereas the benign end results from milder
  loss-of-function/haploinsufficiency. Seizures typically remit between about
  nine months and four years of age, but the developmental encephalopathy
  persists.
parents:
- Epilepsy
- Neurodevelopmental Disorder
- Neurological Disease
synonyms:
- KCNQ2 encephalopathy
- KCNQ2-NEO-DEE
- Neonatal-onset KCNQ2 developmental and epileptic encephalopathy
- Developmental and epileptic encephalopathy 7
- Early infantile epileptic encephalopathy 7
disease_term:
  preferred_term: KCNQ2 developmental and epileptic encephalopathy
  term:
    id: MONDO:0013387
    label: developmental and epileptic encephalopathy, 7
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0013387
      label: developmental and epileptic encephalopathy, 7
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO:0013387 is the KCNQ2 (DEE7) developmental and epileptic
      encephalopathy concept.
inheritance:
- name: Autosomal dominant inheritance
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    KCNQ2-related disorders are inherited in an autosomal dominant manner. Most
    individuals with KCNQ2-NEO-DEE have a de novo pathogenic variant.
  evidence:
  - reference: PMID:20437616
    reference_title: "KCNQ2-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "KCNQ2-related disorders are inherited in an autosomal dominant manner."
    explanation: GeneReviews establishes autosomal dominant inheritance of KCNQ2 disorders.
  - reference: PMID:20437616
    reference_title: "KCNQ2-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most individuals diagnosed with KCNQ2-NEO-DEE have a de novo pathogenic variant."
    explanation: GeneReviews documents that KCNQ2-NEO-DEE is usually de novo.
pathophysiology:
- name: KCNQ2 Pathogenic Variant
  description: >-
    A heterozygous, usually de novo pathogenic variant in KCNQ2 (most often a
    missense variant in the voltage sensor or pore of the Kv7.2 subunit) alters
    the neuronal M channel. In NEO-DEE these variants typically act by a
    dominant-negative mechanism, and a minority are gain-of-function; the milder
    benign end of the spectrum results from simple loss-of-function or
    haploinsufficiency. This node captures the single concept of the initiating
    genetic lesion.
  role: trigger
  gene:
    preferred_term: KCNQ2
    term:
      id: hgnc:6296
      label: KCNQ2
  evidence:
  - reference: PMID:22275249
    reference_title: "KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found 7 different heterozygous KCNQ2 mutations in 8 patients (8/80; 10%); 6 mutations arose de novo."
    explanation: >-
      The Weckhuysen series established de novo heterozygous KCNQ2 missense
      variants as the cause of the neonatal epileptic encephalopathy phenotype.
  downstream:
  - target: Neuronal M Channel Dysfunction
    causal_link_type: DIRECT
    description: >-
      The variant alters the Kv7.2-containing neuronal M channel.
- name: Neuronal M Channel Dysfunction
  description: >-
    KCNQ2 (Kv7.2) co-assembles with KCNQ3 (Kv7.3) to form the neuronal M
    channel. Pathogenic variants reduce or alter M channel function; a
    dominant-negative subunit can suppress channels beyond simple
    haploinsufficiency. This node captures the single concept of the channel
    defect and conforms to the shared epilepsy ion-channel node.
  role: mediator
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Ion Channel and Synaptic Dysfunction"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  molecular_functions:
  - preferred_term: Potassium channel activity
    term:
      id: GO:0005267
      label: potassium channel activity
    modifier: DECREASED
  downstream:
  - target: Loss of M-Current Control of Neuronal Excitability
    causal_link_type: DIRECT
    description: >-
      Reduced M channel function lowers the slow M-current that regulates
      excitability.
- name: Loss of M-Current Control of Neuronal Excitability
  description: >-
    The M-current is a slow, non-inactivating potassium current that stabilizes
    the resting membrane potential and provides a brake on repetitive
    action-potential firing. Its reduction removes this brake, depolarizing
    neurons and permitting sustained firing. This node captures the single
    concept of the excitability-control failure.
  role: mediator
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Regulation of membrane potential
    term:
      id: GO:0042391
      label: regulation of membrane potential
    modifier: DYSREGULATED
  downstream:
  - target: Neuronal Hyperexcitability
    causal_link_type: DIRECT
    description: >-
      Loss of the M-current brake renders neurons hyperexcitable.
- name: Neuronal Hyperexcitability
  description: >-
    Neurons deprived of adequate M-current become hyperexcitable and prone to
    hypersynchronous discharges. This node captures the single concept of
    network hyperexcitability and conforms to the shared epilepsy final common
    pathway.
  role: central_effector
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Neuronal Hyperexcitability and Hypersynchrony"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Neonatal-Onset Seizures with Burst-Suppression EEG
    causal_link_type: DIRECT
    description: >-
      Hyperexcitable neonatal networks produce the seizures and burst-suppression
      EEG of NEO-DEE.
  - target: Neonatal-Onset Developmental Encephalopathy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Early network dysfunction during a critical developmental window
      contributes to the developmental encephalopathy.
- name: Neonatal-Onset Seizures with Burst-Suppression EEG
  description: >-
    The clinical endpoint is multiple daily, mostly tonic seizures beginning in
    the first week of life, accompanied by a burst-suppression or multifocal
    epileptiform EEG. This node captures the single concept of the seizure
    endpoint and conforms to the shared epilepsy final common pathway.
  role: consequence
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:20437616
    reference_title: "KCNQ2-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "KCNQ2-NEO-DEE is characterized by multiple daily seizures beginning in the first week of life that are mostly tonic, with associated focal motor and autonomic features."
    explanation: GeneReviews documents the neonatal-onset multiple daily tonic seizures of NEO-DEE.
  - reference: PMID:20437616
    reference_title: "KCNQ2-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At onset, EEG shows a burst-suppression pattern or multifocal epileptiform activity; early brain MRI can show basal ganglia hyperdensities and later MRIs may show white matter or general volume loss."
    explanation: GeneReviews documents the burst-suppression / multifocal EEG at onset.
- name: Neonatal-Onset Developmental Encephalopathy
  description: >-
    Moderate-to-profound developmental impairment is present and persists even
    after seizures remit (typically between about nine months and four years of
    age), reflecting an encephalopathy that outlasts the active epilepsy. This
    node captures the single concept of the developmental outcome.
  role: effector
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:32239694
    reference_title: "A knock-in mouse model for KCNQ2-related epileptic encephalopathy displays spontaneous generalized seizures and cognitive impairment."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "displays spontaneous generalized seizures and cognitive impairment"
    explanation: >-
      A recurrent-variant knock-in mouse reproduces both the seizures and the
      cognitive impairment, supporting a causal link from M channel dysfunction
      to the developmental encephalopathy.
phenotypes:
- name: Neonatal-Onset Seizures
  description: >-
    Multiple daily seizures begin in the first week of life.
  phenotype_term:
    preferred_term: Neonatal-onset seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:20437616
    reference_title: "KCNQ2-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "KCNQ2-NEO-DEE is characterized by multiple daily seizures beginning in the first week of life that are mostly tonic, with associated focal motor and autonomic features."
    explanation: GeneReviews documents neonatal-onset multiple daily seizures.
- name: Tonic Seizures
  description: >-
    Seizures are mostly tonic, with focal motor and autonomic features.
  phenotype_term:
    preferred_term: Tonic seizure
    term:
      id: HP:0032792
      label: Tonic seizure
- name: EEG with Burst Suppression
  description: >-
    The onset EEG shows a burst-suppression pattern or multifocal epileptiform
    activity.
  phenotype_term:
    preferred_term: EEG with burst suppression
    term:
      id: HP:0010851
      label: EEG with burst suppression
  evidence:
  - reference: PMID:20437616
    reference_title: "KCNQ2-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At onset, EEG shows a burst-suppression pattern or multifocal epileptiform activity; early brain MRI can show basal ganglia hyperdensities and later MRIs may show white matter or general volume loss."
    explanation: GeneReviews documents the burst-suppression EEG at onset.
- name: Apnea
  description: >-
    Autonomic features including apnea may accompany seizures.
  phenotype_term:
    preferred_term: Apnea
    term:
      id: HP:0002104
      label: Apnea
- name: Global Developmental Delay
  description: >-
    Developmental delay is present and persists after seizures remit.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
- name: Intellectual Disability
  description: >-
    Moderate-to-profound intellectual disability is characteristic.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
genetic:
- name: KCNQ2
  gene_term:
    preferred_term: KCNQ2
    term:
      id: hgnc:6296
      label: KCNQ2
  relationship_type: CAUSATIVE
  notes: >-
    KCNQ2 (20q13.33) encodes the Kv7.2 subunit of the neuronal M channel.
    NEO-DEE is usually caused by de novo heterozygous missense variants acting
    by a dominant-negative mechanism (a minority are gain-of-function), which
    reduce M-current more severely than the simple loss-of-function /
    haploinsufficiency variants that cause the benign self-limited end of the
    spectrum.
  evidence:
  - reference: PMID:20437616
    reference_title: "KCNQ2-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most individuals diagnosed with KCNQ2-NEO-DEE have a de novo pathogenic variant."
    explanation: GeneReviews documents the de novo origin of most KCNQ2-NEO-DEE.
diagnosis:
- name: KCNQ2 Molecular Genetic Testing
  description: >-
    Diagnosis is confirmed by identifying a heterozygous pathogenic KCNQ2
    variant on molecular genetic testing in a neonate with the characteristic
    seizure and EEG findings.
  evidence:
  - reference: PMID:20437616
    reference_title: "KCNQ2-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most individuals diagnosed with KCNQ2-NEO-DEE have a de novo pathogenic variant."
    explanation: >-
      Molecular identification of the KCNQ2 variant establishes the diagnosis in
      a proband with the characteristic phenotype.
treatments:
- name: Sodium Channel Blocker Therapy
  description: >-
    Sodium channel blockers (e.g., carbamazepine, phenytoin) are preferentially
    effective in KCNQ2-NEO-DEE; seizure freedom is more likely with these agents
    than with other antiseizure medications - a precision-therapy contrast with
    Dravet syndrome, where sodium channel blockers are avoided.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: carbamazepine
      term:
        id: CHEBI:3387
        label: carbamazepine
    - preferred_term: phenytoin
      term:
        id: CHEBI:8107
        label: phenytoin
  evidence:
  - reference: PMID:20437616
    reference_title: "KCNQ2-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seizure freedom is more likely achieved when receiving sodium channel blockers."
    explanation: >-
      GeneReviews documents the preferential efficacy of sodium channel blockers
      in KCNQ2-NEO-DEE.
- name: M-Channel Opener Therapy
  description: >-
    Kv7/M-channel openers (the prototype ezogabine/retigabine) are the
    mechanistically targeted approach, directly augmenting the deficient
    M-current; ezogabine was withdrawn from market, and next-generation Kv7
    activators are in development.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: ezogabine
      term:
        id: CHEBI:68584
        label: ezogabine
  evidence:
  - reference: DOI:10.1111/epi.17627
    reference_title: "Ezogabine impacts seizures and development in patients with KCNQ2 developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Five individuals had daily seizures at baseline and experienced at least 50% seizure reduction with treatment, sustained in four."
    explanation: >-
      A retrospective series found that the M channel opener ezogabine reduced
      seizures in KCNQ2-DEE, the mechanistically targeted therapy for
      loss-of-function variants.
- name: Antiseizure Medication
  description: >-
    Multiple antiseizure medications are used; NEO-DEE seizures may be resistant
    to combinations.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
datasets: []
discussions:
- discussion_id: gap_kcnq2_gof_vs_lof_opposite_drugs
  prompt: >-
    KCNQ2-NEO-DEE is caused by both dominant-negative loss-of-function and
    gain-of-function variants, which have opposite biophysical effects on the M
    channel yet converge on a severe encephalopathy - how does gain-of-function
    cause disease, and can functional variant classification reliably direct the
    opposite therapies (M channel opener for loss-of-function, avoidance or
    negative modulation for gain-of-function) each requires?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#KCNQ2 Pathogenic Variant
  - pathophysiology#Neuronal M Channel Dysfunction
  rationale: >-
    Most NEO-DEE variants are dominant-negative and reduce M-current, so a Kv7
    opener is the mechanistically correct drug. But a minority are
    gain-of-function, which increase potassium current and would be worsened by
    an opener, plausibly requiring the opposite pharmacology. Because the drug
    that helps one class can harm the other, reliable functional classification
    of each variant is clinically decisive, not merely academic, yet a validated
    rapid variant-to-drug assignment pathway does not exist. Resolving how
    gain-of-function produces encephalopathy and how to triage variants to
    opener versus non-opener strategies is the central precision-therapy gap.
  evidence:
  - reference: DOI:10.1111/epi.17627
    reference_title: "Ezogabine impacts seizures and development in patients with KCNQ2 developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Five individuals had daily seizures at baseline and experienced at least 50% seizure reduction with treatment, sustained in four."
    explanation: >-
      Shows the M channel opener helps loss-of-function-driven seizures; the
      open question is whether the same drug is contraindicated in
      gain-of-function variants, requiring functional triage.
  proposed_experiments:
  - experiment_id: exp_kcnq2_variant_functional_triage
    name: Functional-class-guided drug response in KCNQ2-DEE models
    description: >-
      Classify a panel of NEO-DEE variants as loss-of-function, dominant-negative,
      or gain-of-function by electrophysiology in heterologous cells and patient
      iPSC-derived neurons, then test Kv7-opener versus Kv7-blocker responses to
      determine whether functional class predicts the correct pharmacology.
    experiment_type:
      preferred_term: variant functional classification and drug-response experiment
    readouts:
    - name: Drug response by functional class
      target: pathophysiology#Neuronal M Channel Dysfunction
      biological_processes:
      - preferred_term: Regulation of membrane potential
        term:
          id: GO:0042391
          label: regulation of membrane potential
        modifier: DYSREGULATED
      assays:
      - preferred_term: patch clamp recording
      - preferred_term: multielectrode array recording
      direction: POSITIVE
    controls:
    - name: Wild-type KCNQ2 channels
      description: Wild-type Kv7.2/7.3 channels as the normalization reference.
    decision_criterion: >-
      Functional triage is supported if Kv7 openers normalize excitability for
      loss-of-function and dominant-negative variants but worsen it for
      gain-of-function variants, establishing variant class as a treatment
      selector.
    would_support:
    - pathophysiology#Neuronal M Channel Dysfunction

- discussion_id: gap_kcnq2_same_gene_opposite_severity
  prompt: >-
    What distinguishes the benign self-limited end of the KCNQ2 spectrum
    (self-limited familial neonatal epilepsy, modeled in the Benign Neonatal
    Seizures entry) from the severe NEO-DEE end, given that both arise from
    variants in the same gene?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#KCNQ2 Pathogenic Variant
  - pathophysiology#Neuronal M Channel Dysfunction
  rationale: >-
    KCNQ2 produces a phenotypic continuum from a benign, self-limited neonatal
    epilepsy with normal development to a severe developmental and epileptic
    encephalopathy. The prevailing explanation is that the benign end reflects
    simple haploinsufficiency or mild loss-of-function while the severe end
    reflects dominant-negative suppression (or gain-of-function), producing a
    larger M-current deficit. But this genotype-to-severity map is incomplete,
    and it is the same open question posed from the mild side in the Benign
    Neonatal Seizures entry. A quantitative rule linking residual M-current to
    outcome would let the neonatal genetic diagnosis predict prognosis.
  evidence:
  - reference: PMID:22275249
    reference_title: "KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "KCNQ2 and KCNQ3 mutations are known to be responsible for benign familial neonatal seizures (BFNS)."
    explanation: >-
      Anchors the shared-gene continuum: the same gene underlies the benign end,
      and the severe NEO-DEE end emerged as a distinct phenotype of the same
      gene, framing the severity-determinant gap.
  proposed_experiments:
  - experiment_id: exp_kcnq2_residual_current_severity_map
    name: Residual M-current versus clinical severity mapping
    description: >-
      Across a large set of benign-end and NEO-DEE variants, quantify residual
      M-current (accounting for dominant-negative co-assembly) and correlate it
      with clinical severity and developmental outcome to test whether a
      current-deficit threshold separates the benign from the severe phenotype.
    experiment_type:
      preferred_term: genotype-to-severity correlation experiment
    readouts:
    - name: Residual current versus outcome
      target: pathophysiology#Neuronal M Channel Dysfunction
      assays:
      - preferred_term: patch clamp recording
      direction: POSITIVE
    controls:
    - name: Benign-end variants
      description: Self-limited-epilepsy variants as the mild-end comparator.
    decision_criterion: >-
      A severity determinant is supported if residual M-current (or the degree of
      dominant-negative suppression) separates benign-end from NEO-DEE variants
      and tracks developmental outcome.
    would_support:
    - pathophysiology#KCNQ2 Pathogenic Variant

- discussion_id: gap_kcnq2_seizure_remission_vs_persistent_encephalopathy
  prompt: >-
    Why do KCNQ2-NEO-DEE seizures typically remit between about nine months and
    four years of age while the developmental encephalopathy persists, and is
    the developmental impairment driven by the neonatal seizures and M-current
    loss during a critical window (and therefore reducible by early
    variant-appropriate treatment) or by a seizure-independent developmental
    role of the M channel?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Neonatal-Onset Developmental Encephalopathy
  - pathophysiology#Neonatal-Onset Seizures with Burst-Suppression EEG
  rationale: >-
    The dissociation between remitting seizures and a persistent encephalopathy
    is a defining and puzzling feature of NEO-DEE. If the developmental
    impairment is largely caused by the neonatal seizures and the M-current
    deficit acting during an early critical window, then rapid neonatal genetic
    diagnosis and early variant-appropriate therapy could improve developmental
    outcome. If instead the M channel has a seizure-independent developmental
    role, cognitive prognosis would be more fixed. This determines how much
    developmental benefit to expect from the treat-early-and-right strategy.
  evidence:
  - reference: PMID:32239694
    reference_title: "A knock-in mouse model for KCNQ2-related epileptic encephalopathy displays spontaneous generalized seizures and cognitive impairment."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "displays spontaneous generalized seizures and cognitive impairment"
    explanation: >-
      Provides a model in which seizures and cognitive impairment co-occur, a
      system in which the causal contribution of seizures versus intrinsic
      channel dysfunction to the developmental deficit could be dissected.
  proposed_experiments:
  - experiment_id: exp_kcnq2_early_treatment_developmental_outcome
    name: Early variant-appropriate treatment and developmental outcome
    description: >-
      In a KCNQ2-NEO-DEE knock-in model, apply variant-appropriate therapy
      (M channel opener for loss-of-function, or seizure suppression) at graded
      ages spanning the neonatal window and measure whether earlier seizure
      control improves cognitive and behavioral outcome independently of later
      seizure remission.
    experiment_type:
      preferred_term: early-treatment developmental-outcome experiment
    readouts:
    - name: Cognitive outcome by treatment timing
      target: pathophysiology#Neonatal-Onset Developmental Encephalopathy
      assays:
      - preferred_term: behavioral assay
      - preferred_term: electroencephalography
      direction: POSITIVE
    controls:
    - name: Untreated and wild-type
      description: Matched untreated mutants and wild-type controls.
    decision_criterion: >-
      A seizure/window-driven contribution is supported if earlier treatment
      improves developmental outcome beyond its effect on later seizure
      remission; a seizure-independent developmental role is supported if
      outcome is unchanged by treatment timing.
    would_support:
    - pathophysiology#Neonatal-Onset Developmental Encephalopathy
references:
- reference: PMID:20437616
  title: "KCNQ2-Related Disorders."
  tags:
  - GeneReviews
  findings: []
📚

References & Deep Research

References

1
PMID:20437616
KCNQ2-Related Disorders.
No top-level findings curated for this source.

Deep Research

1
Claude Code ▸
KCNQ2 Developmental and Epileptic Encephalopathy — Research Report
claude-haiku-4-5-20251001, claude-opus-4-8 17 citations 2026-07-17T22:55:00.971954

KCNQ2 Developmental and Epileptic Encephalopathy — Research Report

sup Harry. So this one's a potassium-channel gene that, when it misfires in a newborn's brain, basically turns the volume knob on neuronal firing the wrong way during the most delicate week of a person's life. Here's the whole picture, section by section.

PMID verification key: ✅ = I confirmed the PMID/DOI live this session. 🔶 = citation pulled from a secondary source (GeneReviews, review article) — verify with just fetch-reference before curating, per the DR-verification SOP in CLAUDE.md.

1. Disease Information

What it is. KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE, historically "KCNQ2 encephalopathy" or Early Infantile Epileptic Encephalopathy type 7 / EIEE7) is the severe end of a spectrum of disorders caused by variants in KCNQ2, the gene for the Kv7.2 voltage-gated potassium channel subunit. Think of Kv7.2 as a brake pedal on neurons; when it fails, the neonatal brain seizes in the first days of life and — unlike the benign twin condition — development doesn't recover.

The KCNQ2 spectrum runs from self-limited familial neonatal epilepsy (SLFNE, formerly benign familial neonatal convulsions/seizures) at the mild end, where seizures vanish by 6–12 months and development is normal, to neonatal-onset DEE at the severe end, where the same-timed seizures come with lifelong moderate-to-profound intellectual disability. Same gene, wildly different lives, and the difference is mostly how badly the channel is broken (GeneReviews, KCNQ2-Related Disorders, 2022 update 🔶).

Key identifiers: - OMIM: 613720 (Developmental and Epileptic Encephalopathy 7, DEE7); 121200 (Seizures, benign familial neonatal, 1 / BFNS1); 602235 (the KCNQ2 gene itself) - MONDO: MONDO:0013387 (developmental and epileptic encephalopathy, 7) - Orphanet: ORPHA:439218 (KCNQ2-related developmental and epileptic encephalopathy); the SLFNE end maps to ORPHA:266 - ICD-11: 8A62 (Developmental and epileptic encephalopathies); ICD-10: G40.4 / roughly the "other generalized epilepsy and epileptic syndromes" bucket - MeSH: covered under "Spasms, Infantile" / "Epilepsy, Benign Neonatal" (D020936) and "Epileptic Syndromes" - HGNC gene: hgnc:6296 (KCNQ2)

Synonyms: KCNQ2 encephalopathy, KCNQ2-DEE, EIEE7, DEE7, neonatal-onset KCNQ2-DEE (NEO-DEE); the mild sibling is BFNC/BFNS/SLFNE.

Data provenance. Most knowledge here is aggregated disease-level (case series, functional-genetics cohorts, GeneReviews), not EHR-derived. Patient-registry data exist through the KCNQ2 Cure Alliance and the RIKEE (Rational Intervention for KCNQ2/3 Epileptic Encephalopathy) variant database, but the foundational literature is cohort- and family-based.

2. Etiology

Primary cause: genetic, monogenic. Heterozygous variants in KCNQ2 (chromosome 20q13.33). No environmental or infectious cause — this is a Mendelian channelopathy full stop.

The clean split by variant mechanism (this is the load-bearing concept for the whole disease): - Dominant-negative loss-of-function → severe neonatal DEE. A missense variant makes a poison subunit that drags down the wild-type subunits it co-assembles with, cutting M-current by >50% rather than the ~25% a simple haploinsufficiency would give. This is the classic KCNQ2-DEE mechanism (Miceli et al., 2013 🔶; Weckhuysen et al., 2012, PMID:22275249 ✅). - Simple/partial loss-of-function (haploinsufficiency) → mild SLFNE. Truncations, whole-gene deletions, ~20–30% M-current reduction. Seizures resolve, development normal. - Gain-of-function → a different, non-neonatal-seizure phenotype. GoF variants (e.g., R201C/R201H, R144, R198Q) hyperpolarize channel activation, silence neurons too much, and produce neonatal encephalopathy with non-epileptic myoclonus, later-onset DEE, autism/ID with language impairment — often WITHOUT neonatal seizures. The absence of neonatal seizures is the single best clinical tell for GoF (Mulkey et al., 2017 🔶; Miceli et al., 2015 🔶; the R144 GoF paper, eBioMedicine 2022 🔶).

Risk factors. Essentially none beyond carrying the variant. Because severe KCNQ2-DEE variants are overwhelmingly de novo, there's no meaningful "risk factor" story — no maternal exposure, no prematurity link, no infection. Family history matters only for the milder inherited SLFNE end.

Protective factors. None genetically established. The most interesting "protective" signal is therapeutic timing, not innate: earlier initiation of sodium-channel-blocker therapy may blunt phenotype severity (see §12).

Gene–environment interactions. No established GxE for KCNQ2-DEE. This is about as close to "pure genotype" as neurodevelopmental disease gets.

3. Phenotypes

The core clinical picture, with suggested HPO terms and frequencies drawn from Weckhuysen 2012 (PMID:22275249 ✅) and GeneReviews 🔶:

Phenotype HPO term Onset Frequency Notes
Neonatal-onset seizures Neonatal onset (HP:0003623); Seizure (HP:0001250) Median day 1 of life, almost always first week ~Universal in DEE end Tonic seizures predominate
Tonic seizures Bilateral tonic seizure (HP:0032794) / Tonic seizure (HP:0032792) Neonatal Very frequent Focal-onset tonic stiffening ± clonic, autonomic features
Multiple daily seizures / drug-resistant epilepsy Drug-resistant epilepsy (HP:0032794-adjacent; Intractable seizures HP:0032796) Neonatal Frequent at onset Often many per day initially
Apnea / cyanosis / autonomic features Apnea (HP:0002104) Neonatal Common ictal accompaniment
Moderate-to-profound intellectual disability Intellectual disability, profound (HP:0002187) / severe (HP:0010864) Evident in infancy Defining feature of DEE end Persists after seizures remit
Global developmental delay Global developmental delay (HP:0001263) Infancy Very frequent
Axial hypotonia / appendicular hypertonia Axial hypotonia (HP:0008936); Hypertonia (HP:0001276) Infancy Frequent Mixed tone abnormality is characteristic
Absent/impaired speech Absent speech (HP:0001344) Childhood Frequent (severe end)
Cortical visual impairment Cortical visual impairment (HP:0100704) Infancy Occasional–frequent
Movement disorder (dystonia, dyskinesia) Dystonia (HP:0001332) Later Occasional
Non-epileptic myoclonus (GoF variants) Myoclonus (HP:0001336) Neonatal GoF subtype Distinguishes GoF phenotype
Microcephaly (acquired) Microcephaly (HP:0000252) Postnatal Occasional

Severity/progression pattern (this is the important bit): the seizures are episodic and often remit by age 9 months–4 years, but the encephalopathy is static-to-slowly-improving and lifelong. That decoupling is exactly why the field renamed it from "epileptic encephalopathy" to "developmental AND epileptic encephalopathy" — there's a developmental component that isn't just a consequence of the seizures (the debate is nicely framed in "KCNQ2-DEE: developmental or epileptic encephalopathy?" Epilepsia Open 🔶, PMC7951099).

Quality-of-life impact: severe. Most individuals at the DEE end are nonverbal, non-ambulatory or limited, require full care, and have feeding, communication, and mobility support needs across the lifespan. A 2025 qualitative study of lived experience (Epilepsy & Behavior 🔶) documents high caregiver burden and the developmental-regression fear tied to medication weaning.

4. Genetic / Molecular Information

Causal gene: KCNQ2 (potassium voltage-gated channel subfamily Q member 2), 20q13.33, HGNC:6296, OMIM 602235. Encodes Kv7.2, a 6-transmembrane (S1–S6) voltage-gated K⁺ channel subunit: S1–S4 voltage sensor, S5–S6 pore, and a long intracellular C-terminus with four calmodulin-binding/subunit-assembly helices (A–D).

Discovery lineage (for provenance): - Singh et al., 1998, Nat Genet 18:25–29 — KCNQ2 mutated in BFNC 🔶 (commonly cited PMID:9425895) - Biervert et al., 1998, Science 279:403–406 — potassium channel mutation in neonatal epilepsy 🔶 (PMID:9430337) - Charlier et al., 1998, Nat Genet — KCNQ3 as the second BFNC gene 🔶 (PMID:9425900) - Weckhuysen et al., 2012, Ann Neurol 71:15–25 — carved out the severe encephalopathy phenotype (PMID:22275249 ✅)

Variant classes (ACMG/AMP-classified in ClinVar): - Missense dominates the DEE end (dominant-negative). Recurrent hotspot residues cluster in four high-risk zones: the S4 voltage sensor (e.g., R198, R201, R213, R214), the pore (e.g., around residue 281), the proximal C-terminus, and the C-terminal B-helix (Millichap et al., 2016, Neurol Genet 🔶). Recurrent DEE alleles include R201C/R201H, R213W/R213Q, A294V, and the pore variant G281 series. - Truncating / frameshift / nonsense / whole-gene deletions → generally the milder SLFNE (haploinsufficiency), though not exclusively. - In-frame indels can behave dominant-negatively. - Deletion/duplication (CNV) accounts for <10% of pathogenic findings; sequence analysis catches >90% 🔶.

Allele frequency: DEE-causing variants are absent from population databases (gnomAD) — they're de novo and highly penetrant, so they don't persist in the general population. This absence is itself an ACMG PM2 supporting criterion.

Origin: germline, de novo for the vast majority of DEE cases; germline/gonadal mosaicism in an unaffected parent has been reported and is the reason recurrence risk is quoted as low-but-not-zero (~1–2%+).

Functional consequences: loss-of-function (haploinsufficiency), dominant-negative loss-of-function (the DEE workhorse), and gain-of-function (distinct phenotype). A 2025 paper adds a genuinely novel wrinkle — some DEE variants act by introducing abnormal current inactivation rather than pure current reduction, a fourth biophysical mechanism ("Potassium current inactivation as a novel pathomechanism," PMC12169393 🔶).

Modifier genes / epigenetics / chromosomal abnormalities: no established Mendelian modifier genes, no disease-specific methylation signature (episignature) validated for KCNQ2-DEE as of this writing, and no recurrent large chromosomal rearrangement beyond the 20q13.33 CNVs noted above.

5. Environmental Information

Short section, and honestly a relief to write: no environmental, lifestyle, or infectious contribution is established. KCNQ2-DEE is a de novo monogenic channelopathy. Toxins, radiation, occupational exposure, diet, infection — none are causal or triggering in any documented way. The only "environmental" lever anyone can pull is treatment choice and timing (§12).

6. Mechanism / Pathophysiology

Here's the causal chain, from broken protein to seizing baby. This is the meat for the pathophysiology nodes.

Upstream — the channel and the M-current. Kv7.2 (KCNQ2) co-assembles with Kv7.3 (KCNQ3) into heterotetramers that carry the M-current (I_M / I_Kv7) — a slowly activating, non-inactivating, sub-threshold K⁺ current. Because it's active near resting potential and doesn't inactivate, the M-current is a persistent leak that: 1. sets and stabilizes the resting membrane potential, 2. produces spike-frequency adaptation (it clamps down repetitive firing), and 3. dampens overall neuronal excitability.

Crucially, these channels are concentrated at the axon initial segment (AIS) and nodes of Ranvier, anchored there via ankyrin-G-binding motifs — the exact spots where action potentials are born and propagated (Devaux et al., 2004, "KCNQ2 is a nodal K⁺ channel," J Neurosci, PMID:14762142 ✅; Pan et al., PNAS 🔶). So Kv7.2 isn't a diffuse background brake — it's a brake bolted right onto the ignition switch.

GO / CL / UBERON anchors: - Biological processes: regulation of membrane potential (GO:0042391), potassium ion transmembrane transport (GO:0071805), regulation of neuronal action potential (GO:0098908), negative regulation of neuron differentiation/excitability, spike-frequency adaptation. - Molecular function: voltage-gated potassium channel activity (GO:0005249). - Cellular components: axon initial segment (GO:0043194), node of Ranvier (GO:0033268), plasma membrane (GO:0005886). - Cell types (CL): glutamatergic neuron (CL:0000679), pyramidal neuron (CL:0000598), CNS interneuron / GABAergic interneuron (CL:0000617) — GoF pathology is thought to preferentially silence excitatory neurons or disrupt interneuron circuits. - Anatomy (UBERON): cerebral cortex (UBERON:0000956), hippocampus (UBERON:0002421), brain (UBERON:0000955); the basal ganglia show transient neonatal MRI changes.

Midstream — what the variant does. A dominant-negative missense subunit incorporates into the tetramer and poisons it, so M-current drops >50%. Less brake → the AIS/nodes fire too readily → neuronal hyperexcitability and hypersynchrony → neonatal seizures.

The gain-of-function paradox. GoF variants do the opposite biophysically — too much K⁺ current, neurons over-silenced — yet still cause encephalopathy, likely by disrupting the excitation/inhibition balance at the circuit level (over-silencing excitatory cells, or knocking out interneuron function). This is why the two mechanisms need opposite drugs (Kv7 opener helps LoF, harms GoF).

Downstream — the developmental arm. Kv7 channels aren't just firing regulators; they shape neuronal maturation. A 2025 iPSC study shows LoF variants cause early hyperexcitability followed by maladaptive network remodeling during development (bioRxiv 2025.07.22 🔶), which is the mechanistic candidate for why the developmental deficit outlasts the seizures. That's the crux of the "developmental AND epileptic" reframing.

Conformance note for the KB: the core of this maps cleanly onto the cardiac_ion_channel_repolarization module's sibling logic and, more directly, the epilepsy_excitation_inhibition_imbalance module — KCNQ2-DEE is essentially a textbook conformer of epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance (ion-channel dysfunction → E/I imbalance → hyperexcitability/hypersynchrony → seizures → epileptogenesis). Worth flagging when this entry gets curated.

Molecular profiling: most mechanistic data are electrophysiological (patch-clamp of heterologously expressed channels in Xenopus oocytes / CHO / HEK cells — IN_VITRO evidence) and, increasingly, patient-derived iPSC neurons (also IN_VITRO). No robust transcriptomic/proteomic/metabolomic disease signature from patient tissue exists — you can't biopsy a neonatal brain.

7. Anatomical Structures Affected

  • Organ level: brain (UBERON:0000955) — primarily. This is a CNS-restricted disorder; no systemic organ involvement. Body system: nervous system (central).
  • Regions: cerebral cortex (UBERON:0000956), hippocampus (UBERON:0002421); basal ganglia (UBERON:0002420) show transient neonatal T1/T2 or diffusion changes on MRI; later, nonspecific white-matter changes and volume loss.
  • Tissue/cell level: nervous tissue; neurons — pyramidal/glutamatergic (CL:0000598/CL:0000679) and GABAergic interneurons (CL:0000617). The functional lesion sits at the axon initial segment and nodes of Ranvier.
  • Subcellular: plasma membrane at the AIS (GO:0043194) and node of Ranvier (GO:0033268).
  • Lateralization: bilateral / diffuse encephalopathy; individual seizures are often focal-onset (can shift sides — multifocal) but the disease burden is bilateral.

8. Temporal Development

  • Onset: neonatal, median day 1 of life, essentially always within the first week (Weckhuysen 2012, PMID:22275249 ✅). Onset pattern is acute (dramatic multiple-daily seizures from the start).
  • Course: seizures are frequent and drug-resistant at onset, then typically improve and remit between ~9 months and 3–4 years. The encephalopathy is static-to-lifelong — developmental impairment persists after seizure remission.
  • Stages: (1) neonatal explosive-seizure phase with burst-suppression/multifocal EEG; (2) seizure-attenuation phase in infancy/early childhood; (3) chronic static encephalopathy with variable later-life epilepsy relapse.
  • Progression rate: the neurodevelopmental deficit is non-progressive (static encephalopathy) in most — not a neurodegeneration. Severity is set early.
  • Critical window: the neonatal period is both the window of maximal vulnerability and the proposed window of therapeutic opportunity — the "treat early, treat right" hypothesis (Pisano et al., 2015, Epilepsia, "Early and effective treatment of KCNQ2 encephalopathy" 🔶).
  • Duration: chronic, lifelong disability; seizures self-limit but the disorder does not.

9. Inheritance and Population

Inheritance: autosomal dominant. - KCNQ2-DEE (severe): overwhelmingly de novo; penetrance is complete. Reproduction is rare, so vertical transmission is uncommon. - SLFNE (mild): usually inherited from an affected parent; penetrance incomplete (~77–85%) 🔶. - Germline/gonadal mosaicism occurs and drives the low-but-nonzero sibling recurrence risk. - Anticipation: not a repeat-expansion disorder — no genetic anticipation. - Founder effects / consanguinity: not relevant (dominant, de novo). - Carrier frequency: N/A for the de novo dominant DEE end.

Epidemiology: - KCNQ2 is one of the most common genetic causes of neonatal-onset epileptic encephalopathy — it was found in ~10% of 80 unexplained neonatal/early-infantile seizure-plus-delay cases in the founding cohort (Weckhuysen 2012, PMID:22275249 ✅). - Incidence of KCNQ2-related neonatal epilepsy estimated at roughly ~5.9 per 100,000 live births (<6 months) in a Scottish population cohort (Symonds et al., 2019, Brain 🔶 — verify PMID before curation). - Documented individuals: on the order of a few hundred reported NEO-DEE cases plus ~200 SLFNE families 🔶; it's a rare disease but not vanishingly so among neonatal epilepsies. - Sex ratio: roughly 1:1 — no sex bias (X-autosomal; gene is autosomal). - Geography/ethnicity: no population clustering; reported worldwide across ancestries.

Prevalence class for the KB: qualitatively RARE; incidence ~5.9/100,000 live births → rate_per_100000 ≈ 5.9 (ANNUAL_INCIDENCE / BIRTH_PREVALENCE framing), Orphanet band roughly BAND_1_9_PER_100000.

10. Diagnostics

Genetic testing is the definitive diagnostic. - Approach: clinical suspicion (neonatal tonic seizures + burst-suppression/multifocal EEG + encephalopathy) → next-generation sequencing. Options: multigene neonatal-epilepsy/DEE panel (fastest yield in the NICU), exome/genome sequencing (rapid trio WES/WGS increasingly first-line for neonatal seizures), or single-gene KCNQ2 sequencing. Sequence analysis detects >90%; add deletion/duplication (CMA/MLPA) for the <10% CNV cases 🔶. - Interpretation: classify per ACMG/AMP; DEE variants are typically de novo (PS2), absent from gnomAD (PM2), at known hotspots/recurrent (PS1/PM1/PM5), with functional data (PS3) from patch-clamp — a strong combination that often reaches pathogenic.

Electrophysiology (central to the phenotype): - EEG: at DEE onset, burst-suppression pattern or multifocal epileptiform activity; SLFNE shows normal-to-focal discharges that normalize. Serial EEG is used for surveillance. - Ictal semiology: focal-onset tonic seizures with autonomic/apneic features.

Neuroimaging: - Brain MRI: often normal early, or transient basal ganglia and thalamic hyperintensity/restricted diffusion in the neonatal period; later nonspecific white-matter change or volume loss. MRI helps exclude structural/hypoxic-ischemic mimics rather than confirm KCNQ2-DEE.

Laboratory / biomarkers: no specific blood, CSF, or metabolic biomarker. Routine metabolic workup (glucose, electrolytes, ammonia, lactate, CSF, acylcarnitines, etc.) is done to exclude treatable metabolic/infectious causes of neonatal seizures — it's a rule-out, not a rule-in. No LOINC-coded diagnostic analyte for the disease itself.

Differential diagnosis: other genetic neonatal DEEs — SCN2A, SCN8A, STXBP1, KCNQ3, ARX, CDKL5, KCNT1, pyridoxine-dependent epilepsy (ALDH7A1) and other treatable metabolic epilepsies, and hypoxic-ischemic encephalopathy. KCNQ3 neonatal epilepsy is clinically near-indistinguishable at the mild end.

Screening: KCNQ2 is not on standard biochemical newborn screening (it's not a metabolic disease). Cascade/family testing applies mainly to the inherited SLFNE end. Prenatal/PGT is technically possible when a familial variant is known but is rarely relevant for the de novo DEE cases.

11. Outcome / Prognosis

  • Survival: most individuals survive into adulthood; there is an elevated risk of SUDEP (sudden unexpected death in epilepsy) and mortality from severe-disability complications, but KCNQ2-DEE is not typically early-lethal. Life expectancy is reduced by comorbidity burden, not by a defined disease-specific lethal course.
  • Seizure prognosis: relatively good — seizures usually remit in infancy/early childhood (9 mo–4 yr), though a subset relapse later.
  • Developmental prognosis: poor and the dominant driver of outcome — moderate-to-profound intellectual disability, frequently nonverbal, motor impairment, feeding/communication needs. The encephalopathy persists regardless of seizure control.
  • Prognostic factors: the strongest predictor is variant functional severity — degree of in-vitro M-current reduction correlates with long-term neurodevelopmental outcome (PMC7415140, "Heteromeric Kv7.2 current changes… correlated with long-term neurodevelopmental outcomes" 🔶). Dominant-negative > simple LoF in severity. Earlier effective therapy (sodium-channel blockers) may improve outcome (Pisano 2015 🔶).
  • QoL measures: no KCNQ2-specific validated instrument; generic pediatric DEE/QI-Disability and caregiver-burden tools are used.

12. Treatment

This is where KCNQ2-DEE gets genuinely interesting as a precision-medicine story, because the right drug depends on the biophysics of the variant.

First-line: sodium channel blockers (the standout for loss-of-function). - Carbamazepine, oxcarbazepine, phenytoin, lacosamide. Multiple series show these outperform broad-spectrum ASMs in KCNQ2-DEE. Reported seizure-freedom rates: carbamazepine ~40% within 2 weeks, phenytoin ~33–42%, oxcarbazepine ~53% in one comparison 🔶. - Why it works: Kv7 potassium channels and Naᵥ sodium channels co-localize at the AIS; blocking the sodium channels compensates for the missing potassium brake (down-regulating the excitatory current that the failed K⁺ channel can no longer restrain) 🔶. - MAXO/CHEBI anchors: Pharmacotherapy (NCIT:C15986); agents — carbamazepine (CHEBI:3387), oxcarbazepine (CHEBI:7824), phenytoin (CHEBI:8107), lacosamide (CHEBI:87517). therapeutic_modality: SMALL_MOLECULE.

Targeted / mechanism-based: Kv7 channel openers (retigabine/ezogabine). - Ezogabine (retigabine, XEN496) directly opens Kv7.2/7.3 channels — it's the mechanistically "perfect" drug for loss-of-function variants. A retrospective series (Knight et al., 2023, Epilepsia, DOI:10.1111/epi.17627 ✅) of 8 KCNQ2-DEE patients found ≥50% seizure reduction in the 5 with daily seizures, developmental improvement in all 8, and — tellingly — weaning caused seizure increase, irritability, poor sleep, and developmental regression. - BUT: retigabine was withdrawn from market in 2017 for retinal pigmentation and blue skin/mucosal discoloration with chronic use. A reformulated pediatric version (XEN496/ezogabine) ran a Phase 3 RCT (NCT04639310, EPIK), which was terminated in May 2023 for a sponsor business decision, not safety ✅. So the ideal targeted drug currently has no approved pediatric product — a real unmet-need gap. - Genotype caveat: for gain-of-function variants a Kv7 opener is the wrong direction and can worsen the phenotype; those patients theoretically need Kv7 blockers/negative modulators 🔶. This LoF-vs-GoF drug divergence is the reason functional variant classification matters clinically, not just academically. - MAXO anchor for ezogabine: Pharmacotherapy (NCIT:C15986), agent ezogabine/retigabine (CHEBI:78754), therapeutic_modality: SMALL_MOLECULE, with a target_mechanisms link back to the Kv7/M-current node.

Supportive / adjunctive: phenobarbital (common neonatal first agent, though less specific), levetiracetam, topiramate, benzodiazepines; ketogenic diet (MAXO:0000088, dietary intervention) in refractory cases; standard DEE supportive care — PT/OT/speech, feeding support, developmental services (MAXO:0000950 supportive care; NCIT:C15315 rehabilitation).

Experimental horizon: antisense oligonucleotide and other genetic approaches are in preclinical development (allele-selective knockdown for dominant-negative alleles is a conceptually clean strategy; iPSC/mouse work is underway), and small-molecule Kv7 modulators beyond ezogabine are being pursued. Nothing approved yet.

Pharmacogenomics: the "pharmacogenomics" here IS the disease genotype — LoF vs GoF classification of the KCNQ2 variant is the single most important treatment-guiding factor. This is genotype-guided therapy in its purest form.

13. Prevention

  • Primary prevention: not possible for de novo variants — you can't prevent a spontaneous germline mutation. No vaccine, no modifiable risk factor.
  • Secondary prevention / early detection: the meaningful lever is rapid genetic diagnosis in the NICU (rapid trio exome/genome for neonatal seizures) so that variant-appropriate therapy (sodium channel blockers / Kv7 openers) starts early — the "treat early and right" strategy that may improve developmental outcome (Pisano 2015 🔶). That's secondary prevention of severity, not of the disease.
  • Tertiary prevention: seizure control, SUDEP-risk management, developmental/rehabilitative support to prevent complications.
  • Genetic counseling: essential. For de novo DEE, recurrence risk is low (~1–2%, driven by possible parental gonadal mosaicism); for inherited SLFNE, standard 50% AD transmission with incomplete penetrance. PGT/prenatal testing available when a familial variant is known (MAXO:0000079 genetic counseling; NSGC/ACMG frameworks).
  • Immunization / public-health / environmental interventions: not applicable.

14. Other Species / Natural Disease

  • Taxonomy / orthologs: KCNQ2 is deeply conserved. Mouse Kcnq2 (NCBITaxon:10090, Mus musculus), rat Kcnq2 (NCBITaxon:10116), zebrafish kcnq2 (NCBITaxon:7955). Human ortholog KCNQ2 (NCBI Gene 3785).
  • Natural disease in animals: no well-documented spontaneous naturally-occurring KCNQ2 neonatal epilepsy in companion animals or wildlife is catalogued in OMIA the way, say, some canine epilepsies are. The disease knowledge is essentially all human + engineered models.
  • Comparative biology: the M-current and Kv7.2/7.3 AIS localization are conserved across mammals, which is why rodent models recapitulate the human electrophysiology well — the brake pedal is built the same way across species.
  • Zoonosis / transmission: N/A — genetic, non-transmissible.

15. Model Organisms

Rodent models are strong here and are the backbone of mechanistic and preclinical-therapeutic work. Evidence source = MODEL_ORGANISM.

  • Conditional dominant-negative Kcnq2 transgenic mice (Peters et al., 2005): suppress M-current → spontaneous seizures, hippocampal memory impairment, behavioral hyperactivity — an early demonstration that M-current loss alone produces the seizure+cognitive phenotype 🔶.
  • Knock-in point-mutant mice reproducing human alleles:
  • Kcnq2 Thr274Met/+ knock-in — viable, spontaneous generalized seizures from ~P20–P30 with cognitive impairment (Milh/Marini group, 2020, Epilepsia, PMID:32239694 ✅). A faithful DEE-like model.
  • Kcnq2 A306T and Kcnq3 G311V knock-ins — survive into adulthood with spontaneous lifelong seizures 🔶.
  • Calmodulin-binding-domain variant mice — spontaneous seizure + memory loss (PMC8713762 🔶).
  • cKcnq2 M547V conditional mice — early mortality, spontaneous seizures, enhanced seizure susceptibility, memory deficits, repetitive behaviors 🔶.
  • Tg Kcnq2 G279S mice — partial seizures ± secondary generalization 🔶.
  • Conventional Kcnq2 knockout: homozygous null is neonatal-lethal (pulmonary/dysfunctional), consistent with the channel's essential role — hence the field's reliance on heterozygous and conditional models. Good review: Brun et al., 2022, "Mouse models of Kcnq2 dysfunction," Epilepsia 🔶.
  • iPSC-derived human neuron models (IN_VITRO): patient-derived and CRISPR-engineered iPSC neurons now recapitulate variant-specific hyperexcitability and drug responses, including the 2025 machine-learning-phenotyping and maladaptive-remodeling studies (bioRxiv 2025 🔶) — increasingly used for variant functional classification and drug screening.
  • Heterologous expression (IN_VITRO): Xenopus oocytes and CHO/HEK cells for patch-clamp are the standard for scoring a new variant as LoF/DN/GoF — the assay that feeds the ACMG PS3 criterion and the treatment decision.

Model strengths: rodent knock-ins reproduce spontaneous seizures, cognitive deficits, and the electrophysiology, and respond to Kv7 openers — good for preclinical drug testing. Limitations: rodents don't fully model the human developmental/cognitive trajectory or the neonatal timing precisely; homozygous KO lethality limits complete-loss modeling; and human-specific circuit biology is only approximated (a candidate HUMAN_MODEL_MISMATCH discussion note for the KB where mouse timing/severity diverges from human).

Resources: MGI (mouse), RGD (rat), ZFIN (zebrafish), IMPC/KOMP for Kcnq2 alleles; the RIKEE database (rikee.org) as the human variant-function registry.

Curation notes for the dismech entry

A few things worth carrying into the YAML when this gets built: - Module conformance: strong candidate conformer for epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance (ion-channel dysfunction → E/I imbalance → hyperexcitability/hypersynchrony → seizures). The Kv7-opener treatment pattern fits the target_mechanisms drug convention. - The LoF/DN/GoF split should be modeled explicitly (probably as subtypes or mechanistic_hypotheses with hypothesis_group_id), since it drives both phenotype and opposite-direction treatment. - Evidence-source discipline: electrophysiology and iPSC data = IN_VITRO; mouse knock-ins = MODEL_ORGANISM; keep the neonatal-seizure/EEG/outcome claims on HUMAN_CLINICAL sources (Weckhuysen 2012, Knight 2023). - Verify before committing: PMIDs marked �remaining (Singh 9425895, Biervert 9430337, Charlier 9425900, Miceli 2013/2015, Millichap 2016 27353566, Mulkey 2017, Symonds 2019) came from GeneReviews/reviews — run just fetch-reference and confirm snippets are exact substrings per the anti-hallucination SOP. The ones I confirmed live this session are Weckhuysen (22275249), Devaux nodal K⁺ (14762142), the Thr274Met mouse (32239694), and the Knight ezogabine paper (DOI 10.1111/epi.17627).

Sources: - GeneReviews: KCNQ2-Related Disorders (NBK32534) - OMIM #613720 — DEE7 · OMIM *602235 — KCNQ2 · OMIM #121200 — BFNS1 - Orphanet: KCNQ2-related DEE (439218) · NORD: KCNQ2-DEE - Weckhuysen et al. 2012, Ann Neurol (PMID:22275249) - Devaux et al. 2004, KCNQ2 is a nodal K⁺ channel (PMID:14762142) - Knight et al. 2023, Ezogabine in KCNQ2-DEE, Epilepsia · NCT04639310 (XEN496/EPIK) - Knock-in Kcnq2 Thr274Met mouse (PMID:32239694) · Brun et al. 2022, Mouse models of Kcnq2 dysfunction - KCNQ2-DEE: developmental or epileptic encephalopathy? (PMC7951099) · Heteromeric Kv7.2 current & outcomes (PMC7415140) - Potassium current inactivation as novel pathomechanism (PMC12169393) · R144 gain-of-function, eBioMedicine 2022 - KCNQ2 Cure Alliance — What is KCNQ2 Epilepsy

That's the whole animal, nose to tail. The one-line version if you're skimming: it's a de novo dominant potassium-channel brake failure that seizes newborns in week one, the seizures fade but the brain stays hurt, and — unusually — knowing whether the channel is too weak or too strong literally flips which drug you reach for. Want me to go ahead and scaffold the actual kb/disorders/KCNQ2_Developmental_and_Epileptic_Encephalopathy.yaml entry from this, or open a curation issue for it?